HOME >> MEDICINE >> NEWS
GroPep starts Phase 1 infertility trial

GroPep's program - to develop a treatment for a condition that potentially causes 50% of all miscarriages - reached a major milestone today with commencement of recruitment of healthy women volunteers into a Phase 1 trial of its infertility drug, PV903.

The drug is targeted to treat recurrent miscarriages caused by an abnormal immune response to the foetus a condition for which there is no current treatment.

The market for a drug to treat this condition is estimated to be up to US$750 million annually.

Listed biopharmaceutical company GroPep Limited (ASX:GRO) announced today that it will commence a Phase 1 trial of its infertility drug PV903. The trial, which will be conducted under the Therapeutic Goods Administration Clinical Trial Notification scheme, was approved by the Royal Adelaide Hospital Research Ethics Committee.

Recruitment will begin immediately to allow medical screening and enrolment of the first cohort of subjects in mid-February 2006. The results of the trial should be known in late 2006, depending on recruitment rate.

The trial, conducted at the CMAX Adelaide-based facilities, involves healthy female volunteers each receiving a single administration of PV903 gel (or placebo) as they are enrolled sequentially into three groups with the PV903 dose escalating between groups. A total of 36 volunteers will complete the trial. The objectives of the trial are to evaluate the safety and tolerability of vaginally administered PV903 gel, and to determine whether PV903 has effects on vaginal immune cells in a manner consistent with its proposed role in treating immunebased infertility.

Over 50% of miscarriages have no apparent explanation and some scientists believe that women who suffer from repeated miscarriage have an immune system that attacks the embryo as "foreign". PV903 is a recombinant version of a protein that is naturally found in semen and thought to be re
'"/>

Contact: Mr Tony Mitchell
61-283-547-700
Research Australia
9-Jan-2006


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep completes final milestone of the path malaria vaccine initiative
3. GroPep to pursue promising asthma drug following preclinical study results
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Coffee jump-starts short-term memory
7. Epidemiology in Europe: the problem starts in childhood
8. GSK announces launch of largest ever Phase III trial in lung cancer treatment
9. Phase II study shows combination improves survival of metastatic melanoma patients
10. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
11. Drug combination proves effective against myeloma in Phase I trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2019)... Pa. (PRWEB) , ... August 21, 2019 , ... ... celebrity Golden Retriever mascot from Morgantown, Pennsylvania, a lovable, socially popular, registered ... on August 22 called Never Bean Better Day. The Registrar at National Day ...
(Date:8/21/2019)... Calif. (PRWEB) , ... August ... ... to announce a revolutionary advancement in automated x-ray inspection technology: HDRX imaging. ... and minimized false rejects. More importantly, HDRX can deliver high image resolution ...
(Date:8/19/2019)... ... August 19, 2019 , ... Nearly ... Organic Skin Care products , the authorized retailer will change its corporate name ... practicing esthetician in Florida providing Eminence Organic Skin Care facials and treatments. DeVries ...
(Date:8/19/2019)... ... , ... Professional Enrollment Concepts (PEC), a top benefits enrollment ... ranked #3056 on the 2019 Inc. 5000 Fastest-Growing Private Companies list. The list ... successful companies within the American economy's most dynamic segment—its independent small and mid-sized ...
(Date:8/19/2019)... , ... August 18, 2019 , ... ... today launches its third product, Aqua+, adding two SKUs to its line of ... faster and more effectively than water alone. Distinguishing Aqua+ from other rehydration solutions ...
Breaking Medicine News(10 mins):
(Date:8/21/2019)... Md. (PRWEB) , ... August 21, 2019 , ... As ... first experiences with being evaluated or treated for speech and language disorders through the ... are worried about their child’s communication: Recent national polling commissioned by the ...
(Date:8/21/2019)... (PRWEB) , ... August 21, 2019 , ... The latest ... and is now available on the company’s global website. , Crystallography Times is a ... and serves the X-ray analysis community by presenting the latest news and crystallographic research. ...
(Date:8/21/2019)... BOSTON (PRWEB) , ... August ... ... today announced the latest release of its Wellness Check Module for its ... rehabilitation centers perform more effective wellness checks on their discharged patients. ...
Breaking Medicine Technology:
Cached News: